Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01051856 · ClinicalTrials.gov registry record · Phase 4
TissueLink Versus SEAMGUARD After Distal Pancreatectomy
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
NCT01051856: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT01051856 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01051856, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this research study is to find a lowest leak rate following a distal pancreatectomy (removal of the left side of the pancreas). Distal pancreatectomy is known to have a risk of pancreatic leaks (leakage of pancreatic fluid from the cut surface of the pancreas). Two FDA cleared devices (TissueLink and SEAMGUARD) will be studied to treat and prevent leaks at the end of the pancreas.
Interventions
- DEVICE SEAMGUARD with bioabsorbable staple
- PROCEDURE TissueLink with radiofrequency ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01051856
The ClinicalTrials.gov registry entry for NCT01051856 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SEAMGUARD with bioabsorbable staple is the first listed.
NCT01051856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01051856 about?
NCT01051856 is a clinical study titled "TissueLink Versus SEAMGUARD After Distal Pancreatectomy". The purpose of this research study is to find a lowest leak rate following a distal pancreatectomy (removal of the left side of the pancreas). Distal pancreatectomy is known to have a risk of pancreatic leaks (leakage of pancreatic fluid from the cut surface of the pancreas). Two FDA cleared devices...
What is the current status of trial NCT01051856?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2009-12. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01051856?
The interventions under investigation include: SEAMGUARD with bioabsorbable staple (DEVICE), TissueLink with radiofrequency ablation (PROCEDURE).
Who is sponsoring clinical trial NCT01051856?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.